JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Pseudophakic pupillary-block glaucoma in children.

We studied 16 children, ranging in age between 3 and 8 years, who had posterior chamber intraocular lens implantation and developed inflammatory pupillary-block glaucoma. Prophylactic peripheral iridectomy had not been performed in any of the eyes. The patients were treated medically, and YAG laser iridotomy was performed successfully one week after initial control of intraocular pressure. Of 16 eyes in which intraocular pressure remained uncontrolled, trabeculectomy was necessary in three eyes and irreversible glaucomatous visual loss occurred in two eyes. Our data demonstrate the need for stringent and more frequent postoperative follow-up of children after intraocular lens implantation, especially during the first four postoperative weeks. Careful long-term follow-up for treatment after cataract is mandatory to prevent development of amblyopia.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app